Novo is paying Gensaic up to $354 million per target in upfront fees and development and commercial milestones, plus tiered ...

Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...

Privately-held Cambridge, USA-based biotech Gensaic announced a potentially lucrative license and discovery collaboration ...

Total deal value of up to $354 million in upfront, development, and commercial milestone payments per target plus tiered ...